Erin Allman‑Updyke
speaker
983 appearances
2 recordings
1 series
first heard Sep 2026
last heard 4d ago
Erin Allman‑Updyke’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 2 in all, peaking in Sep 2026 with 2.
Appearances
This is the thing, you know, we don't we don't necessarily know.
Certainly no.
And there probably isn't, right?
Like the things that cause psychosis in schizophrenia are probably not exactly the same things that are causing treatment resistant depression, right?
That doesn't make sense that those are the same exact thing, but we can treat both of them with something like ECT.
So it it's really interesting.
And and really, like we talked about last week, Erin.
ECT works.
It is remarkably effective.
One of the main indications for ECT, one of the main reasons that we use it, especially here in the States and in a lot of, you know, European countries and Australia and New Zealand is treatment-resistant depression.
And that can be depression with or without psychosis and with or without suicidal ideation.
It can be unipolar or bipolar depression.
But most of the studies on remission and response rates are remarkable.
We can see anywhere from like 50 to 60% or more remission, meaning you have essentially no depressive symptoms, like you have gone into quote-unquote remission.
And response rates, meaning improvement in your depressive symptoms, can be anywhere from 60 to 90% in some studies.
And when we compare this to SSRIs, which we talked about in a prior episode.
They have a remission rate at best of around 40%, right?
There's also data that ECT can cut readmission rates in the first 30 days in half.
Um, it's not perfect.
There is certainly still the risk of remission in the first six to twelve months, especially, or the risk of relapse essentially.
Showing 681–700 of 983 · page 35 of 50
← Previous
Next →